Pentoxifylline Treatment in Acute Pancreatitis (AP) (AP)
Pentoxifylline Treatment in Acute Pancreatitis: A Double-Blind Placebo - Controlled Randomized Trial
Sponsor: Mayo Clinic
This PHASE3 trial investigates Acute Pancreatitis (AP) and Alcoholic Pancreatitis and is currently completed. Mayo Clinic leads this study, which shows 11 recorded versions since 2015 — indicating substantial longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.
Status Flow
Change History
11 versions recorded-
Sep 2024 — Present [monthly]
Completed PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE3
-
Jan 2023 — Jul 2024 [monthly]
Completed PHASE3
-
Dec 2022 — Jan 2023 [monthly]
Completed PHASE3
-
Jan 2021 — Dec 2022 [monthly]
Completed PHASE3
▶ Show 6 earlier versions
-
Feb 2019 — Jan 2021 [monthly]
Completed PHASE3
-
Jun 2018 — Feb 2019 [monthly]
Completed PHASE3
-
Mar 2018 — Jun 2018 [monthly]
Completed PHASE3
Status: Unknown Status → Completed
-
Feb 2018 — Mar 2018 [monthly]
Unknown Status PHASE3
Status: Enrolling By Invitation → Unknown Status
-
Feb 2017 — Feb 2018 [monthly]
Enrolling By Invitation PHASE3
-
Jan 2017 — Feb 2017 [monthly]
Enrolling By Invitation PHASE3
First recorded
May 2015
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Mayo Clinic
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
For direct contact, visit the study record on ClinicalTrials.gov .